Well, the Greek Debt Crisis has come to a conclusion, a default; and US stocks seem to be back to normal. This leaves us with a bit of a mixed market in biotech today. Nonetheless, even in mixed or poor markets, there are always opportunities that are well worth taking advantage of. With that said, I’ve dug up four stocks that I think are great opportunities: MannKind Corporation (NASDAQ:MNKD), Gilead Sciences, Inc. (NASDAQ:GILD), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Biocept Inc (NASDAQ:BIOC).
MannKind Corporation has been a company that I’ve been enthusiastic about ever since I heard about Afrezza. However, with the weak pre-launch, the price of the stock has been driven down quite a bit. Nonetheless, I’m not too concerned. It’s important to take pre-launch sales data for what it is. The reality is that Afrezza has seen no advertising; yet that is! I’ve had the opportunity to speak with several members of the diabetic community about the inhaled insulin and no one knew about it until I mentioned it. However, once they knew, they wanted to try it out! Which leads us to why I think MNKD will see gains relatively soon. Within weeks, Afrezza will be pushed into the Direct-to-Consumer campaign; building awareness and sales. From there, I’m expecting to see big uptrends that last for quite some time. So, keep your eyes peeled as opportunity is just around the bend!
Gilead Sciences, Inc.
Gilead Sciences is one of my favorite companies in biotech. With control over the HIV and HCV treatment markets, they’ve got quite the story to tell. However, their stock price doesn’t necessarily reflect that. When AbbVie started to move into the HCV sector, investors took note and were scared to push Gilead Sciences’ stock value too high. As a result, GILD is now one of the most undervalued stocks on the market today; with a P/E ratio of below 10! In time, I’m expecting to see big gains; especially after the release of Gilead Sciences’ next earnings report. So, if you’re looking for an opportunity, watch GILD closely.
Synergy Pharmaceuticals Inc
Synergy Pharmaceuticals has had a rough time over the past week or so. About two weeks ago, the company announced study results from its candidate known as plecanatide. The positive results pushed the stock up. However, following the gains, a correction ensued. Then, the Greek debt crisis drug the stock down even further. Nonetheless, I stayed confident in the fact that SGYP was trading low and would pop up; and that it has. Currently (11:48), SGYP is trading at $9.48 per share after a gain of 4.18% so far today; making it the second day in a row with decent gains. With the reasoning for the gains, I’m not expecting to see any major declines any time soon. So, if you’re not already in, you may want to consider looking for pull-backs as they present great opportunities.
Finally, we have Biocept. Yesterday, the company announced that it has launched its FGFR1 amplification testing. The test is designed to help physicians identify paitients who may be receptive to specific lung and breast cancer treatments. As a result, BIOC soared in the market yesterday. However, as I predicted, we’re seeing a bit of a correction today. Currently (11:58), BIOC is trading at $2.68 per share after a loss of 1.87%. However, I’m not concerned. After great increases, it’s not uncommon to see declines in a stock. Nonetheless, it may be time to look for support as this climb is likely to continue!
Don’t be late to the party – Click Here to see what 4500 Wall Street Analysts say about your stocks.